Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/41937
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDecoster, L.-
dc.contributor.authorAftimos, P. G.-
dc.contributor.authorRottey, S.-
dc.contributor.authorPrenen, H.-
dc.contributor.authorCollignon, J. J.-
dc.contributor.authorMEBIS, Jeroen-
dc.contributor.authorCanon, J-L.-
dc.contributor.authorFastenaekels, V.-
dc.contributor.authorCappoen, N.-
dc.contributor.authorJoris, S. R.-
dc.contributor.authorDe Greve, J.-
dc.date.accessioned2023-12-15T08:27:48Z-
dc.date.available2023-12-15T08:27:48Z-
dc.date.issued2023-
dc.date.submitted2023-12-15T07:41:10Z-
dc.identifier.citationANNALS OF ONCOLOGY, 34 , p. S262-
dc.identifier.urihttp://hdl.handle.net/1942/41937-
dc.description.abstractBackground: The Belgian Precision initiative aims to implement tumor-agnostic NGS in advanced cancer patients (pts) and enhance access to genotype-matching drugs. The current study aimed to investigate the efficacy of afatinib in advanced pre-treated solid cancers with an EGFR (excluding non-small cell lung cancer (NSCLC)), HER2 or HER3 mutation.-
dc.description.sponsorshipKom op tegen kanker-
dc.publisherELSEVIER-
dc.subject.otherInterests, Personal, Full or part-time Employment: CDR-Life-
dc.subject.otherOther, Personal, Project Lead: CDR-Life L Borras: Financial Interests, Personal, Full or part-time Employment: CDR-Life-
dc.subject.otherFinancial Interests, Personal, Leadership Role: CDR-Life-
dc.subject.otherFinancial Interests, Personal, Stocks/Shares: CDR-Life S Biswas: Financial Interests, Personal, Full or part-time Employment: CDR-Life R Leidner: Financial Interests, Personal, Advisory Role: Bristol Myers Squibb-
dc.subject.otherFinancial Interests, Personal, Project Lead: Bristol Myers Squibb, Incycte E Calvo: Financial Interests, Personal, Advisory Board: Adcendo, Amunix, Anaveon, AstraZeneca, BMS, Janssen, MonTa, MSD, Nanobiotix, Nouscom, Novartis, Servier, Tar- gImmune, T-knife, Chugai, Elevation Oncology, Ellipses Pharmacy, SyneosHealth, Genmab, Diac- curate-
dc.subject.otherFinancial Interests, Personal, Invited Speaker: OncoDNA, PharmaMar, Roche/Genentech-
dc.subject.otherFinancial Interests, Personal, Full or part-time Employment, Director, Clinical Research: HM Hospi- tales Group-
dc.subject.otherFinancial Interests, Personal, Full or part-time Employment, Medical Oncologist Clinical Investigator Director, Clinical Research: START Madrid -CIOCC (Centro Integral Oncológico Clara Campal)-
dc.subject.otherFinancial Interests, Personal, Member of Board of Directors, External Independent member of Board of Directors: PharmaMar-
dc.subject.otherFinancial Interests, Personal, Ownership Interest: START, Oncoart Associated-
dc.subject.otherFinancial Interests, Personal, Steering Committee Member, Member of Data Monitoring Committee: BeiGene, Sanofi, Merus-
dc.subject.otherFinancial Interests, Personal, Steering Committee Member: Novartis-
dc.subject.otherNon-Financial Interests, Other, Non-for-profit Foundation President and co-founder: INTHEOS (Investigational Therapeutics in Oncological Sciences) non-for-profit Foundation-
dc.subject.otherNon- Financial Interests, Advisory Role: PsiOxus-
dc.subject.otherNon-Financial Interests, Other, Chair of the Independent-
dc.titleAfatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateOCT 20-24, 2023-
local.bibliographicCitation.conferencenameAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO)-
local.bibliographicCitation.conferenceplaceBarcelona, SPAIN-
dc.identifier.spageS262-
dc.identifier.volume34-
local.format.pages1-
local.bibliographicCitation.jcatM-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.doi10.1016/j.annonc.2023.09.2924-
dc.identifier.isi001087480200196-
local.provider.typewosris-
local.description.affiliation[Decoster, L.] Univ Ziekenhuis Brussel, UZ Brussel, Dept Med Oncol, Jette, Belgium.-
local.description.affiliation[Aftimos, P. G.] Inst Jules Bordet, Clin Trials Conduct Unit, Anderlecht, Belgium.-
local.description.affiliation[Rottey, S.] Univ Hosp Ghent, Dept Med Oncol, UZ Gent, Ghent, Belgium.-
local.description.affiliation[Prenen, H.] Univ Hosp Antwerp, UZA, Oncol Dept, Edegem, Belgium.-
local.description.affiliation[Collignon, J. J.] CHU Liege Sart Tilman, Serv Oncol, Dept Med Oncol, Liege, Belgium.-
local.description.affiliation[Mebis, J.] Jesse Ziekenhuis, Dept Med Oncol, Campus Virga Jesse, Hasselt, Belgium.-
local.description.affiliation[Canon, J-L.] GHdC Grand Hop Charleroi, Dept Oncol Hematol, Site Notre Dame, Charleroi, Belgium.-
local.description.affiliation[Fastenaekels, V.; Cappoen, N.; Joris, S. R.] Univ Ziekenhuis Brussel, UZ Brussel, Med Oncol, Jette, Belgium.-
local.description.affiliation[De Greve, J.] Vrije Univ Brussel, Med Oncol Dept, Fac Med & Pharm, Brussels, Belgium.-
local.uhasselt.internationalno-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
item.fullcitationDecoster, L.; Aftimos, P. G.; Rottey, S.; Prenen, H.; Collignon, J. J.; MEBIS, Jeroen; Canon, J-L.; Fastenaekels, V.; Cappoen, N.; Joris, S. R. & De Greve, J. (2023) Afatinib for EGFR, HER2 or HER3 mutated solid tumors: A phase II Belgian precision study. In: ANNALS OF ONCOLOGY, 34 , p. S262.-
item.contributorDecoster, L.-
item.contributorAftimos, P. G.-
item.contributorRottey, S.-
item.contributorPrenen, H.-
item.contributorCollignon, J. J.-
item.contributorMEBIS, Jeroen-
item.contributorCanon, J-L.-
item.contributorFastenaekels, V.-
item.contributorCappoen, N.-
item.contributorJoris, S. R.-
item.contributorDe Greve, J.-
crisitem.journal.issn0923-7534-
crisitem.journal.eissn1569-8041-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
201P Afatinib for EGFR, HER2 or HER3 mutated solid tumors_ A phase II Belgian precision study.pdfPublished version71.86 kBAdobe PDFView/Open
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.